Disruptive technology for the treatment of hemophilia

(Children's Hospital Los Angeles) An international team of hematologists including Guy Young, MD, of Children's Hospital Los Angeles, has found that in patients with hemophilia A with inhibitors, a novel therapy called emicizumab, decreases incidence of bleeding episodes by 87 percent. Results of this multicenter phase III study called HAVEN 1, will be presented at the International Society of Thrombosis and Hemostasis and published in the New England Journal of Medicine on July 10.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news